Maple Securities USA’s Vertex Pharmaceuticals VRTX Stock Holding History

Maple Securities USA’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-4,848	Closed	-$572K	–	318
2015 Q1	$572K	Buy	4,848 +1,310	+37%	+$157K	0.05%	98
2014 Q4	$420K	Buy	+3,538	New	+$398K	0.03%	90
2014 Q3	–	Sell	-5,119	Closed	-$485K	–	315
2014 Q2	$485K	Buy	+5,119	New	+$359K	0.05%	83

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Maple Securities USA's VRTX Position: Q2 2015 in Review

Maple Securities USA sold out of Vertex Pharmaceuticals (VRTX) in Q2 2015, closing a stake of 4,848 shares — an estimated $572K sold.

Maple Securities USA first reported a position in VRTX in Q2 2014 and held it in 3 quarters. The position peaked at $572K in Q1 2015. 500 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

Maple Securities USA reported no remaining Vertex Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Maple Securities USA sold 4,848 Vertex Pharmaceuticals shares in Q2 2015, an estimated $572K.
Maple Securities USA first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Maple Securities USA's Vertex Pharmaceuticals position peaked at $572K in Q1 2015.
500 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on Maple Securities USA's 13F filing for Q2 2015, filed 24 Jul 2015.